Chloprime 200 T Tablet contains Chlorpromazine 200 mg and Trihexyphenidyl 2 mg, a combination formulation developed for the management of various psychiatric and psychotic disorders under medical supervision. The medicine combines the antipsychotic action of Chlorpromazine with the protective anticholinergic effects of Trihexyphenidyl, helping provide effective symptom control while minimizing certain movement-related adverse effects associated with long-term antipsychotic therapy. This balanced approach supports improved treatment adherence and patient comfort.

Chlorpromazine acts by influencing dopamine receptors in the brain, helping control symptoms such as hallucinations, delusions, agitation, aggression, disorganized thinking, and behavioral disturbances. Trihexyphenidyl helps reduce extrapyramidal symptoms including muscle stiffness, tremors, rigidity, and involuntary movements that may occur during treatment with antipsychotic medicines. Together, these ingredients offer comprehensive therapeutic support for patients requiring ongoing psychiatric care.

The tablet is commonly prescribed for schizophrenia, psychotic disorders, severe behavioral disturbances, and other psychiatric conditions as determined by a healthcare professional. Regular treatment may help stabilize mental health symptoms, improve social and occupational functioning, and support overall quality of life. The dosage regimen should be individualized according to the patient's clinical condition, response to treatment, and ongoing medical assessment.

With the growing emphasis on mental health awareness and the increasing demand for effective psychiatric treatment options, Chloprime 200 T Tablet continues to maintain strong relevance in the neuropsychiatry segment. Its established therapeutic role, physician acceptance, and utility in comprehensive psychiatric management contribute to consistent market demand. The product offers valuable business opportunities and sustainable growth potential for retailers and distributors operating within the psychiatric pharmaceutical sector.

Chloprime 200 T Tablet may cause drowsiness, dizziness, dry mouth, constipation, blurred vision, low blood pressure, weight gain, tremors, restlessness, or difficulty concentrating. Some individuals may experience movement disorders, mood changes, or other serious adverse effects requiring medical attention.

Chloprime 200 T Tablet is indicated for schizophrenia, psychotic disorders, severe behavioral disturbances, and other psychiatric conditions as advised by a healthcare professional. It also helps manage extrapyramidal symptoms associated with antipsychotic therapy.

This medication should be used only under the supervision of a qualified healthcare professional. Patients should avoid alcohol consumption and activities requiring mental alertness until they understand how the medicine affects them. Regular medical monitoring may be necessary during treatment. The medicine should not be discontinued abruptly without consulting a healthcare professional.

Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of tampering.